The potential of proton beam radiation therapy in head and neck cancer

Acta Oncologica

Volumn 44, Issue 8, 2005, Pages 876-880

  Ask, Anders ^a   Björk Eriksson, Thomas ^b   Zackrisson, Björn ^c   Blomquist, Erik ^d   Glimelius, Bengt ^d,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEAM THERAPY; CANCER CONTROL; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; EXPERIENCE; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROTON RADIATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; THYROID CARCINOMA;

COST-BENEFIT ANALYSIS; HEAD AND NECK NEOPLASMS; HEALTH CARE COSTS; HUMANS; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SWEDEN;

EID: 28844448270     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500355991     Document Type: Review

References (61)

1. Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol 2003;42:443-61.
2. American Joint Committee on Cancer. Manual for staging of cancer, 4th ed. Philadelphia: Lippincott; 1992.
3. Lee WR, Mendenhall WM, Parsons JT, Million RR, Cassisi NJ, Stringer SP. Carcinoma of the tonsillar region: a multivariate analysis of 243 patients treated with radical radiotherapy. Head Neck 1993;15:283-8.
4. Cancer Incidence in Sweden. Epidemiologiskt Centrum 2003; www.sos.se.
5. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-8.
6. Pignon JP, Bourkis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment of head and neck squamous carcinoma: Three meta-analyses of updated individual data, MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
7. Bourhis J, Pignon JP. Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy? Hematol Oncol Clin North Am 1999;13:769-75, vii.
8. Argiris A. Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol 2002;14:323-9.
9. Argiris A. Induction chemotherapy for head and neck cancer: will history repeat itself? J Natl Compr Cane Netw 2005;3:393-403.
10. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
11. Hanna E, Alexiou M, Morgan J, Badley J, Maddox AM, Penagaricano J, et al. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 2004;130:861-7.
12. Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 2004;22:3061-9.
13. Bonner JA, Giralt J, Harari PM, Azarnia N, Cohen R, Raben D, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol 2004;22(No.14S):5507.
14. Robbins RJ, Schlumberger MJ. The evolving role of (131) I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005;46(Suppl 1):28S-37.
15. Lin JD, Tsang NM, Huang MJ, Weng HF. Results of external beam radiotherapy in patients with well differentiated thyroid carcinoma. Jpn J Clin Oncol 1997;27:244-7.
16. Eisbruch A, Foote RL, O'Sullivan B, Beitler JJ, Vikram B. Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 2002;12:238-49.
17. Bourhis J, Etessami A, Wilbault P, Lusinchi A, Calais G, Lapeyre M, et al. Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations. Curr Opin Oncol 2004;16:215-9.
18. Hall CE, Harris R, A'Hern R, Archer DJ, Rhys-Evans P, Henk JM, et al. Le Fort I osteotomy and low-dose rate Ir192 brachytherapy for treatment of recurrent nasopharyngeal tumours. Radiother Oncol 2003;66:41-8.
19. Kakimoto N, Inoue T, Inoue T, Murakami S, Furukawa S, Yoshida K, et al. Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol 2003;68:123-8.
20. Stannard CE, Hering E, Hough J, Knowles R, Munro R, Hille J. Post-operative treatment of malignant salivary gland tumours of the palate with iodine-125 brachytherapy. Radiother Oncol 2004;73:307-11.
21. Mazeron JJ. Brachytherapy: a new era. Radiother Oncol 2005;74:223-5.
22. Hammerlid E, Silander E, Hornestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer - a longitudinal study. Head Neck 2001;23:113-25.
23. Duke RL, Campbell BH, Indresano AT, Eaton DJ, Marbella AM, Myers KB, et al. Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope 2005;115:678-83.
24. Bussels B, Maes A, Flamen P, Lambin P, Erven K, Hermans R, et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol 2004;73:297-306.
25. Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev 2002;28:65-74.
26. Dijkstra PU, Kalk WW, Roodenburg JL. Trismus in head and neck oncology: a systematic review. Oral Oncol 2004;40:879-89.
27. Mavroidis P, Laurell G, Kraepelien T, Fernberg JO, Lind BK, Brahme A. Determination and clinical verification of dose-response parameters for esophageal stricture from head and neck radiotherapy. Acta Oncol 2003;42:865-81.
28. Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation retinopathy. Ophthalmology 1982;89:1494-501.
29. Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation optic neuropathy. Ophthalmology 1982;89:1489-93.
30. Buys NS, Kerns TC, Jr. Irradiation damage to the chiasm. Am J Ophthalmol 1957;44:483-6.
31. Bhandare N, Monroe AT, Morris CG, Bhatti MT, Mendenhall WM. Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys 2005;62:1070-7.
32. Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005;62:672-9.
33. Turner SL, Tiver KW, Boyages SC. Thyroid dysfunction following radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 1995;31:279-83.
34. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44.
35. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRTand IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8.
36. Milecki P, Szyfter K, Skowronek J. Risk of postirradiation induction of cancer of the modern methods of radiotherapy (3D CRT and IMRT) head and neck cancer]. Otolaryngol Pol 2004;58:887-93.
37. Verhey LJ, Munzenrider JE. Proton beam therapy. Annu Rev Biophys Bioeng 1982;11:331-57.
38. Suit H, Goitein M, Munzenrider J, Verhey L, Blitzer P, Gragoudas E, et al. Evaluation of the clinical applicability of proton beams in definitive fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1982;8:2199-205.
39. Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg 1997;123:34-40.
40. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, McIntyre J, Adams J, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 2002;94:2623-34.
41. Slater JD, Yonemoto LT, Mantik DW, Bush DA, Preston W, Grove RI, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys 2005;62:494-500.
42. Brown AP, Urie MM, Chisin R, Suit HD. Proton therapy for carcinoma of the nasopharynx: a study in comparative treatment planning. Int J Radiat Oncol Biol Phys 1989;16:1607-14.
43. Lomax AJ, Bortfeld T, Goitein G, Debus J, Dykstra C, Tercier PA, et al. A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol 1999;51:257-71.
44. Lomax AJ, Goitein M, Adams J. Intensity modulation in radiotherapy: photons versus protons in the paranasal sinus. Radiother Oncol 2003;66:11-8.
45. Cozzi L, Fogliata A. IMRT in the treatment of head and neck cancer: is the present already the future? Expert Rev Anticancer Ther 2002;2:297-308.
46. Cozzi L, Fogliata A, Lomax A, Bolsi A. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol 2001;61:287-97.
47. Johansson J, Blomquist E, Montelius A, Isacsson U, Glimelius B. Potential outcomes of modalities and techniques in radiotherapy for patients with hypopharyngeal carcinoma. Radiother Oncol 2004;72:129-38.
48. Miralbell R, Crowell C, Suit HD. Potential improvement of three dimension treatment planning and proton therapy in the outcome of maxillary sinus cancer. Int J Radiat Oncol Biol Phys 1992;22:305-10.
49. Slater JM, Slater JD, Archambeau JO. Carcinoma of the tonsillar region: potential for use of proton-beam therapy. Int J Radiat Oncol Biol Phys 1992;22:311-9.
50. Mock U, Georg D, Bogner J, Auberger T, Potter R. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 2004;58:147-54.
51. Krengli M, Liebsch NJ, Hug EB, Orecchia R. Review of current protocols for protontherapy in USA. Tumori 1998;84:209-16.
52. Möller TR, Brorsson B, Ceberg J, Frodin JE, Lindholm C, Nylen U, et al. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol 2003;42:387-410.
53. Svensson H, Möller T. Developments in radiotherapy. Acta Oncol 2003;42:430-42.
54. Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 2001;37:84-93.
55. Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Vini L, Harmer C, et al. Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol 2001;60:173-80.
56. Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 2001;59:161-7.
57. Duncan W. An evaluation of the results of neutron therapy trials. Acta Oncol 1994;33:299-306.
58. Schulz-Ertner D, Nikoghosyan A, Jakel O, Haberer T, Kraft G, Scholz M, et al. Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. Int J Radiat Oncol Biol Phys 2003;56:391-8.
59. Lundkvist J, Ekman M, Rehn Ericsson S, Jönsson B, Glimelius B. Proton therapy of cancer: Potential clinical advantages and cost-effectiveness. Acta Oncol 2005;44:850-61.
60. Lievens Y, Van den Bogaert W. Proton beam therapy: too expensive to become true? Radiother Oncol 2005;75:131-3.
61. Buus S, Grau C, Munk OL, Bender D, Jensen K, Keiding S. 11C-methionine PET, a novel method for measuring regional salivary gland function after radiotherapy of head and neck cancer. Radiother Oncol 2004;73:289-96.